New Developments in Antiviral Therapy for Chronic Hepatitis B Infection

References

• Greenberg H B, Pollard R B, Lutwick L I, Gregory P B, Robinson E S, Merigan T C. Effect of human leucocyte interferon on hepatitis B virus infection in patients with chronic active hepatitis. N Engl J Med 1976; 295: 517–22
   PubMed Web of Science ®Google Scholar
• Perillo R P, Schiff E R, Davis G L, Bodenheimer H C, Lindsay K, Payne J, et al. A randomized controlled trial of interferon alfa-2b alone and after prednisone withdrawal for the treatment of chronic hepatitis B. N Engl J Med 1990; 323: 295–301
   PubMed Web of Science ®Google Scholar
• Eurohep-Executive team on antiviral therapy. The treatment effect of alpha-interferon in chronic hepatitis B is independent of pretreatment variables—results of a meta-analysis of individual patient data. J Hepatol 1992; 16: S22, (abstract)
   Google Scholar
• Wong D HK, Cheung A M, O'Rourke K, Naylor C D, Detsky A S, Heathcote J. Effect of alpha-interferon in patients with hepatitis Be antigen positive chronic hepatitis B: a meta-analysis. Ann Intern Med 1993; 119: 312–23
   PubMed Web of Science ®Google Scholar
• Janssen H LA, Brouwer J T, van der Mast R C, Schalm S W. Suicide associated with alpha-interferon therapy for chronic viral hepatitis. J Hepatol 1994, In press
   PubMedGoogle Scholar
• Janssen H LA, Brouwer J T, Nevens F, Fevery J, Marcellin P, Sanchez-Tapias J M, et al. Fatal decompensation of chronic viral hepatitis associated with alpha-interferon treatment. Br Med J 1993; 306: 107–8
   PubMed Web of Science ®Google Scholar
• Takano S, Omata M, Yokosuka O, Imazeki F, Ohto M. Effects of antiviral agents on chronic hepatitis B. Analysis using Cox proportional hazard model. Dig Dis Sci 1992; 37: 1633–43
   PubMedGoogle Scholar
• Perillo R P. Factors influencing response to interferon in chronic hepatitis B: implications for Asian and Western populations. Hepatology 1990; 12: 1433–5
   PubMedGoogle Scholar
• Marinos G, Smith H M, Naoumov N V, Williams R. Quantitative assessment of serum IgM anti-HBc in the natural course and during interferon treatment of chronic hepatitis B infection. Hepatology 1994; 19: 303–11
   PubMedGoogle Scholar
• Janssen H LA, Berk L, Schalm S W, Heijtink R A, Hess G, Rossol S, et al. Antiviral effect of prolonged intermittent lymphoblastoid alpha-interferon treatment in chronic hepatitis B. Gut 1992; 33: 1094–8
   PubMedGoogle Scholar
• Nair P V, Tong M J, Stevenson D, Roskamp D, Boone C. A pilot study on the effects of prednisone withdrawal on serum hepatitis B virus DNA and HBeAg in chronic active hepatitis B. Hepatology 1986; 6: 1319–24
   PubMedGoogle Scholar
• Krogskaard K. Does corticosteroid pretreatment enhance the effect of alpha-interferon treatment in chronic hepatitis B?. J Hepatol 1994; 20: 159–62
   PubMedGoogle Scholar
• Berk L, Schalm S W, de Man R A, Heijtink R A, Berthelot P, Brechot C, et al. Failure of acyclovir to enhance the antiviral effect of alpha-lymphoblastoid interferon on HBe-seroconversion in chronic hepatitis B. J Hepatol 1992; 14: 305–9
   PubMedGoogle Scholar
• Garcia G, Smith C I, Weisberg J I, Eisenberg M, Bisset J, Nair P V, et al. Adenine arabinoside monophosphate (Vidarabine phosphate) in combination with human leucocyte interferon in the treatment of chronic hepatitis B. Ann Intern Med 1987; 107: 278–85
   PubMed Web of Science ®Google Scholar
• Janssen H LA, Berk L, Heijtink R A, ten Kate F JW, Schalm S W. Alpha-inteiferon and zidovudine combination therapy for chronic hepatitis type B. Results of a randomized placebo-controlled trial. Hepatology 1993; 17: 383–8
   PubMedGoogle Scholar
• Fried M W, DiBisceglie A M, Straus S E, Savarese B, Beames M P, Hoofnagle J H. FIAU, a new oral anti-viral agent, profoundly inhibits HBV DNA in patients with chronic hepatitis B. Hepatology 1992; 16: 127A, (abstract)
   PubMed Web of Science ®Google Scholar
• Macilwain C. NIH, FDA seek lessons from hepatitis B drug trial deaths. Nature 1993; 364: 275
   PubMedGoogle Scholar
• Chang C N, Skalski V, Zhou J H, Cheng Y C. Biochemical pharmacology of (+) and (-) 2′-3′ dideoxy-3′thiacytidine as anti-hepatitis B virus agents. J Biol Chem 1992; 267: 22414–20
   PubMed Web of Science ®Google Scholar
• Tyrell D LJ, Fischer K, Cameron J. 2′3′Dideoxy-3-'thiacytidine (Lamivudine) treatment of chimpanzees chronically infected with hepatitis B virus (HBV) resulted in a rapid suppression of HBV DNA in sera. Proceedings of the International symposium on viral hepatitis and liver disease, Tokyo, May, 10–141993, 156, (abstract)
   Google Scholar
• Kruining J, Heijtink R A, Schalm S W. Antiviral agents in hepatitis B virus transfected cell lines: inhibitory and cytotoxic effect related to time of treatment. J Hepatol 1994, In press
   Google Scholar
• de Man R A, Schalm S W, Main J, Thomas H C, Fevery J, Nevens F, Staley H. A dose-ranging study to determine the antiviral activity and safety of Lamivudine (2′-deoxy-3′thiacytidine) in patients with chronic hepatitis B infection. Gut 1993; 34: S5, Suppl: (abstract)
   Google Scholar
• Gerlich W, Heerman K H, Thomssen R. Eurohep trial on generation of reference samples for hepatitis B virus DNA. Comm of Eur Communities: Advances in Medical Biology, C Baya. IOS Press, Amsterdam 1994; 249–50
   Google Scholar
• Tsiquaye K, Sutton D, Maung M, Boyd M R. Pharmacokinetics and antiviral activities of Penciclovir and Famciclovir in Pekin Ducks chronically infected with Duck hepatitis B virus. Proceedings of the IAAC. New Orleans 1993; 1594
   Google Scholar
• Benner K G, Lee R G, Keeffe E B, Lopez R R, Sasaki A W, Pinson C W. Fibrosing cytolytic liver failure secondary to recurrent hepatitis B after liver transplantation. Gastroenterology 1992; 103: 1307–12
   PubMedGoogle Scholar
• Köck J, Schlicht H J. Analysis of the earliest steps of hepadnavirus replication: genome repair after infectious entry into hepatocytes does not depend on viral polymerase activity. J Virol 1993; 67: 4867–74
   PubMed Web of Science ®Google Scholar
• Mason W S, Cullen J, Saputelli J, Wu T T, Liu C, London W T, et al. Characterisation of the antiviral effects of 2′carbodeoxy-guanosine in Ducks chronically infected with Duck hepatitis B virus. Hepatology 1994; 19: 398–411
   PubMedGoogle Scholar